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Abstract
Due to numerous drawbacks with current modes of treatment for various ocular diseases, researchers are synthesizing
drug dispensing contact lenses. The lenses will contribute to greater bioavailability of the drug, the minimization of negative side effects, and increased patient compliance. As treatment for glaucoma, in vivo studies have been conducted with
latanoprost, timolol maleate, and brimonidine tartrate-eluting lenses, and have succeeded in reducing intraocular pressure
to desired values (Ciolino et al., 2016), (Schultz and Mint, 2002). As treatment for fungal keratitis, in vitro studies prove
that econazole and natamycin-eluting contact lenses have been successful in killing 100% of fungi for sustained periods of
time (Ciolino et al., 2011), (Phan et al., 2013). Finally, for allergic conjunctivitis, contact lenses containing nanoparticles of
prednisolone have been synthesized and demonstrate effective drug-releasing capabilities (ElShaer et al., 2016).
Introduction

Glaucoma

Current methods of treatment for various ocular ailments include both oral medications and topical eye drops. There are
significant downsides to both. Orals are often not the first line of
treatment both because, they take a circuitous route to the eye
and cause many more negative systemic side effects (Kim, et al.,
2014). Next, in the case of eye drops, there are multiple barriers
to overcome. First, much of the dispensed eye drop is inhibited
by pre-corneal factors which include nasolacrimal drainage, tearing, and blinking.These factors significantly lower the bioavailability of the medication. Research indicates that only a fraction of
the precious medication, a mere one percent to seven percent,
reaches its required destination, thereby reducing the drug’s effectiveness (Schultz and Mint, 2002). Furthermore, the drops are
often administered by the patient, and sometimes are required
multiple times a day. This commonly leasds to low patient compliance, and doses are frequently forgotten or skipped purposely
(Ciolino et al., 2011). Given the above, there exists an impetus to
develop alternate methods of delivering ocular medications, thus
enabling effective treatment. Researchers are currently working
on developing a contact lens that will also dispense nanoparticles
of medication directly into the eye while correcting refractive
error. In patients who don’t have refractive error, the contact
lenses can simply be worn for the purpose of delivering the
needed medication into their eyes. The use of contact lenses for
ocular drug delivery can solve many of the issues associated with
eye drops. First, the space created by the lens with the cornea
has limited tear mixing, and potentially a greater amount of contact time between the drug and the cornea.

Glaucoma, a group of conditions that damages the eye’s
optic nerve, usually results from increased intraocular pressure (IOP) which can result in vision loss and blindness. The
two main forms are open-angle glaucoma and angle-closure
glaucoma. Both forms, involve clogging of the eye’s drainage
canals, leading to elevated ocular pressures and subsequent
nerve damage. In open-angle glaucoma this leads to a gradual
increase in IOP because, the angle between the iris and cornea
is wide and open. In angle-closure glaucoma there is a sudden

This causes greater bioavailability. Additionally, there is an
added benefit of eliminating the need for multiple doses a day,
which will increase the amount of patient compliance. Under
ideal kinetics, the drug will release in a time dependent manner, extending the therapeutic effects of one dose (Phan et al.,
2014). Research with a drug dispensing contact lens (DDCL), is
currently underway for a number of ocular conditions. In this
work specifically, a DDCL for the diseases of glaucoma, fungal
keratitis, and hay fever are discussed.

38

Limited space
between lens
and cornea

increase in IOP because, the angle between the iris and cornea
is either very narrow or closed. Current methods of treatment
include surgery, oral medications, and eye drops, depending on
the classification and extent of the disease. When surgery is
warranted however, it usually does not resolve the increased
IOP completely and generally a regimen of eye drops are prescribed as well post operatively. Additionally, surgery can cause
negative side effects including, cataract formation, inflammation, ocular infections, corneal issues, and low IOP. Negative
side effects caused by oral medications can include irritation,
stinging, redness, blurred vision, itchiness, low blood pressure,
fatigue, shortness of breath, headaches, dry mouth, frequent
urination, upset stomach, and memory problems, depending
on the class of drug prescribed. In general, topical eye drops
are the first line of treatment. However, due to the issues
posited above, a contact lens that can dispense anti-glaucoma
drugs is currently being developed.

Are Contact Lenses an Effective Vehicle for Ocular-Disease Drug Delivery?

Research for Anti-Glaucoma Drug Dispensing
Contact Lens
Joseph B. Ciolino, MD, at the Massachusetts Eye and Ear, conducted an in vivo study on the effectiveness of a Latanoprostdispensing contact lens for female monkeys with induced
glaucoma. Latanoprost is currently on the market as a topical
anti-glaucoma eye drop. It belongs to a class of anti-glaucoma
medications knows as prostaglandin analogues, which work to
lower the IOP by increasing uveoscleral flow (although more recently research suggests that it may occur through a trabecular
pathway) and it is prescribed for cases of open-angle glaucoma
(Lindén and Alm, 1999, Winkler and Fautsch, 2013). In Ciolino’s
research, a thin latanoprost-polymer film was introduced into
a methafilcon hydrogel contact lens. Both a low-dose contact
lens (CL), and a high-dose CL were synthesized. The intraocular
pressure of the glaucomatous monkeys was monitored after a
period of the following cases:
1.

Treatment with Latanoprost eye drops

2.

Treatment with CL-low

3.

Treatment with CL-high

4.

No treatment

The results demonstrated that the latanoprost eye drops succeeded in reducing IOP approximately 5 mmHg, the CL-lo by
about 6.5 mmHg, and CL-hi by about 11 mmHg.
Evidently, “Sustained delivery of latanoprost by contact lenses is
at least as effective as delivery with daily latanoprost ophthalmic solution. More research is needed to determine the optimal continuous-release dose that would be well tolerated and
maximally effective. Contact lens drug delivery may become an
option for the treatment of glaucoma and a platform for ocular
drug delivery (Ciolino et al., 2016)”
Additional anti-glaucoma contact lenses that are currently being
researched, synthesized, and patented are those that contain
timolol maleate or brimonidine tartrate within a polymeric hydrogel.Timolol maleate belongs to a class of anti-glaucoma drugs
known as beta-adrenergic blockers and brimonidine tartrate is
an alpha agonist. Both are prescribed for cases of open-angle
glaucoma. Specifically, in the case of beta blockers, systemic side
effects can be pretty severe such as, cardiac arrhythmias, bronchospasm, and stroke and is therefore prescribed based on a
patient’s complete medical history. The aim of the study was
to develop contact lenses that maintain normal hydration and
comfort, and will dispense lower doses of drug for extended
periods of time. This will lead to increased patient compliance,

decreased negative side effects, and efficacious treatment
(Schultz and Mint, 2002).
Etafilcon contact lenses (hydrogels) were washed in a saline
solution and briefly dried. Then they were immersed in either a
dilute solution of brimonidine tartrate (0.02%), or a dilute solution of timolol maleate (0.05%). (Topical ophthalmic solutions of
the above drugs are commercially available as 0.2% solutions for
brimonidine, 0.25% for timolol, and 0.5% for timolol ophthalmic
gel forming solution). The lenses were subsequently tested on
multiple patients as a replacement for their current regimens of
eye drops. Instead of the patient administering their daily eye
drop, he wore the contact lens for 30 minutes each day. In all
cases, this method allowed for IOP to remain below the necessary value of 20 mmHg, with no evidence of ocular toxicity.
An additional study was conducted on glaucomatous beagle
dogs. NIGHT & DAY™ silicone hydrogel contact lenses were
immersed in timolol and phosphate buffered saline solution.
Then, one lens was inserted into one of the dog’s eyes, while
the other eye served as the control, and no lens was inserted.
The lenses with similar dosing to timolol eye drops led to an
IOP reduction of about 5 mmHg (which is slightly greater than
the IOP reduction resulting from timolol eye drops). However,
lenses with a third drug loading as the eye drops led to a similar
reduction in intraocular pressure, suggesting increased bioavailability. Finally, the eye without the contact lens remained unaffected by its proximal lens, which suggests reduction in systemic
absorption of the drug released by the lens (Peng et al., 2012).

Fungal Keratitis
Fungal keratitis is an infection of the cornea (the clear, round
dome covering the eye’s iris and pupil) which causes pain, reduced vision, light sensitivity, and tearing or discharge from the
eye. Resulting from infection from contact lens use, or from
injury to the eye, fungal keratitis usually develops very quickly,
and if left untreated, can cause blindness (Boyd, 2015). Fungal
keratitis is also prevalent in tropical and subtropical climates
(Ciolino et al., 2011).
Current treatment options for fungal keratitis vary depending
on the severity of the condition. Topical eye drops are often
the first line of treatment (Ciolino et al., 2011). Once again the
above drawbacks to eye drops are present:
“The failures of topical antimycotic treatments may be
related to the limitations of eye drops as a form of drug
delivery. Eye drops generate a transiently high concentration on application followed by a short period of effective therapeutic concentration and then a prolonged
period of underdose. Furthermore, each drop is diluted
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and washed away by reflex tearing and dispersed by
blinking. As a consequence, only 1% to 7% of drug in a
drop is absorbed in the eye. The cornea absorbs only
a fraction of this dose, in part due to the tissue’s short
contact time with the topical drops (Ciolino et al.,
2011).”
Currently there is only one drug available on the market, natamycin, as a topical ophthalmic antifungal. However, this drug
specifically is shown to have poor corneal penetration and is
mainly effective with superficial corneal infections caused by
Fusarium species (Singh, 2015). Depending on the severity and
identity of the disease, often subconjunctival injections of an
antifungal agent are prescribed and the dosage times are not
infrequent, (twice every hour for the first 24 hours, then once
every hour for the next 24 hours etc). “Successful antifungal
therapy for fungal keratitis requires frequent drug administration for prolonged periods (ie, at least 12 weeks) (Singh, 2015).”
Sometimes antifungals in an oral form are prescribed. However,
15 to 27 percent of patients with fungal keratitis require surgical
intervention (Boyd, 2015). Even after surgery, a course of topical
drops is often prescribed as well. Finally, surgery is not effective
in all cases, and a patient may be rendered significantly visually
impaired (Singh, 2015).

Research for an Anti-Fungal Contact Lens
The ineffectiveness of the topical regiment arises from low
penetrance of the drug to the corneal epithelium as well as
inadequate contact time between drug and tissue. Additionally,
low patient compliance is common due to the frequency with
which the drug needs to be administered. A contact lens that
dispenses antifungal particles could resolve all these issues. A
prototype antifungal contact lens (Ciolino et al., 2011) was synthesized using the following method:

The lenses were also tested for their drug-releasing capabilities.
The testing was conducted by immersing the lenses in a yeast
nitrogen base medium and incubated.Then they were immersed
in fresh medium every 24 hours. The yeast nitrogen base drug
release medium was collected at different intervals, and diluted
with new medium containing C. albicans. Once again after a period of dilution and incubation, the suspension was plated and
counted for viable colonies.
The results showed that both methods were capable of killing
100% of fungi for extended intervals.The release medium which
contained contact lenses with 16 mg of econazole (PLGA-16)
killed 100% of fungi for 21 days! The mediums from contact
lenses, containing lower concentrations of econazole, killed fungus for shorter amounts of time. In the cases where the contact
lenses came directly in contact with the fungal suspension, 100%
of fungi were killed for 8 to 10 days (with PLGA-16). Studies
show that C. albicans is more difficult to kill than Fusarium
species. Therefore if Candida was killed by econazole, Fusarium
should be as well (Ciolino et al., 2011). (Currently econazole is
not FDA approved for ophthalmic use, although many ophthalmologists would prefer to treat fungal infections with something other than Natamycin, currently the only available drug).
Contact lenses that could elute the drug natamycin have also
been synthesized (Phan et al., 2013). The study focused specifically on manipulating various contact lens materials. Hydrogels
were composed of:
1. 100 % pHEMA,
2. 85% pHEMA and 15% [Tris(trimethylsiloxy)silyl]-propyl
methacrylate (TRIS)
3. 75% pHEMA and 25% TRIS

Econazole, an antifungal drug, was added to a film of poly (lactic-co-glycolic) acid (PLGA). PLGA is desirable because of its
biocompatibility and biodegradability, and its effectiveness at
controlling drug release kinetics. Various film sizes were synthesized and all were encapsulated into polyhydroxymethacrylate (pHEMA), a common contact lens material. Contact lenses
were synthesized with different concentrations of econazole.
A control lens was created as well which contained the PLGA
film inside the pHEMA hydrogel without the econazole. The
contact lenses were tested against the fungus C. albicans, a
common agent of fungal keratitis. First the lenses were placed
directly onto a rich medium, a culture plate containing 1 mL of
the Candida suspension. After a number of cycles of incubation
and refreshing the medium, the culture was diluted, incubated,
and counted for viable colonies. This was done to determine
the effect of the contact lenses in direct contact with the fungi.
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4. N,N-dimethylacrylamide (DMAA),
5. 85% DMAA and 15% TRIS
6. 75% DMAA and 25% TRIS
The lenses were monitored by their uptake and release of two
forms of natamycin. The first form was Natamycin dissolved in
deionized water, and the second form was Natamycin encapsulated within poly(D,L-lactide)-dextran nanoparticles. Results
indicated that the optimal materials to use were those containing DMAA. Furthermore, all gels had a greater uptake with the
nanoparticles of natamycin versus natamycin alone. Finally, the
release of natamycin within nanoparticles was greater than the
natamycin alone. Also, the first hour of release was noteworthy.

Are Contact Lenses an Effective Vehicle for Ocular-Disease Drug Delivery?

The lenses with regular natamycin released 28-82% within the
first hour. In the nanoparticle lenses this was reduced to 21-54%
(Phan et al., 2013).

MAA (methacrylic acid) and a small amount of EGDMA (ethylene glycol dimethacrylate) were mixed together along with
the PNPs.These four hydrogel materials were allowed to polymerize thermally for 4 hours at 80°C in molds of polypropylene.

Hay Fever and Allergic Conjunctivitis
“Spring allergies are triggered as trees start blooming and billions of pollen grains are released into the air, causing susceptible individuals to develop allergic rhinitis… In these patients,
the pollen causes degranulation of mast cells, which contain
inflammatory mediators, ie, histamine and other allergy-causing
chemicals.This process is clinically represented by sneezing; red,
tearing eyes; postnasal drip; sinus headaches; feelings of sinus
fullness; and itchy, scratchy throat (Medscape, 2016).”
As the conjunctiva of the eye is a mucosal membrane, it too is
subjected to the inflammatory responses of allergic rhinitis. Per
the CDC (Center for Disease Control and Prevention), approximately 19 million adults and another 6 million children suffer
from hay fever in the U.S. alone. For the ocular symptoms of rhinitis, also known as allergic conjunctivitis, eye drops containing
anti-histamines and/or mast cell stabilizers can be prescribed or
recommended. Another class of treatments are corticosteroids
and glucocorticoids, which also work to reduce the allergic
reactions which affect the eye and relieve the negative symptoms. These can be prescribed as an ophthalmic suspension for
topical use. Once again due to inhibitive pre-corneal factors, an
alternate drug delivery mechanism is currently being researched
in the form of a drug dispensing contact lens.

Research for DDCLs for Allergic Conjunctivitis
The Kingston University London conducted an in vitro experiment to synthesize a contact lens that could dispense nanoparticles of a synthetic glucocorticoid, prednisolone, into the eyes
of patients with allergic conjunctivitis. (Currently prednisolone
is on the market as prednisolone acetate ophthalmic suspension
for topical use.) The main purpose of the experiment was to
consider the effects of the encapsulated drug on the contact
lenses’ functionality and safety as well as the drug’s bioavailability (ElShaer et al., 2016).
Prednisolone nanoparticles (PNP) were synthesized using an
emulsion-solvent evaporation method. The experiment was designed to maximize three key nanoparticle features: small particle size (increased surface area/bioavailability), highest encapsulation efficiency, and maximum surface charge (no coagulation
of particles; increases stability). To obtain the smallest particle
size, four variables were manipulated: PLGA (poly-lactic-co-glycolic acid), PVA (polyvinyl alcohol), API (amount of prednisolone
used), and homogenization time. Through optimization of these
components a particle size of about 295 nm was obtained. To
form the contact lens molds, HEMA (2-hydroxymethacrylate),

The in vitro drug release pattern of the contact lens with 0.4
grams of PNP was observed to be a two-phase process: an initial burst, followed by a period of slower release. The lens was
placed in a release medium of phosphate buffered saline for 24
hours. 10.8% of drug was released in that time.The slow release
of the drug can be due to the need for the drug to get past its
nanoparticle barrier and through the contact lens as well. One
of the issues with eye drops is that all of the drugs are released
within a few hours. Nanoparticles of medication embedded in
contact lenses can provide a longer lasting therapeutic regimen
(ElShaer et al., 2016).

Method of Drug Release from Contact Lens
Although some studies for drug-eluting contact lenses pre-soak
the contact lenses in drug, to allow for eventual diffusion into
the eye, to achieve a more controlled method of release, other
methods are being researched. The human tear film contains an
enzyme called lysozyme. In a study on anti-glaucoma contact
lenses, timolol maleate was encapsulated in nanodiamond (ND)
particles. The NDs were coated in both polyethyleneimine (PEI)
and chitosan. Chitosan is an enzyme-cleavable polysaccharide
and PEI enables a more effective cleavage. The drug release of
these impregnated lenses was monitored in vitro. In the absence
of lysozyme, no release of timolol maleate was detected. In the
presence of lysozyme the lens released 9.41 micrograms in 24
hours (Kim et al., 2014).

Addition of Drug to Contact Lens Material and
Subsequent Hydration and Oxygen Permeability
This feature was monitored in the prednisolone study cited
above. Contact lenses lacking the PNPs had an average hydration of about 36%. Lenses containing a smaller volume
of drug nanoparticles (0.2 g) had a decreased hydration
by about 31%, whereas the lenses with a higher volume of
PNPs (0.4 g) had a further reduction in hydration to about
30.5%.
Surface wettability determines comfort of the lens, and was
measured as well. A good surface wettability is identified by a
contact angle less than 90 °C. Unmodified lenses have a contact angle of 85 °C. The prednisolone encapsulated lenses had
further reduced angles which should increase ocular comfort
(ElShaer et al., 2016). Similarly, contact lenses containing nanodiamond particles of timolol maleate demonstrated acceptable
hydration values (Kim et al., 2014).
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Transparency/light Transmission Capability of
Drug-Impregnated Lens
Ideally a contact lens should have a light transmittance of
above 90%, so vision is unobstructed. The control contact
lenses (lacking PNP) in the prednisolone study had a high
transparency of 94.5%. The lenses containing 0.2 grams and
0.4 grams of PNP had a reduced transparency of 86.23% and
83.1% respectively. However, this amount contributes to low
or no opacity, and as long as the correct amount of nanoparticle is added to the lens, vision should not be compromised
(ElShaer et al., 2016). Similarly, addition of nanodiamond particles of timolol maleate to a pHEMA lens did not cause any
discernable changes to the lens’ optical clarity. The lens with
a higher concentration of NDs maintained a transmittance of
84.5% (Kim et al., 2014).

Dimensions/measurements of Drug-Eluting
Contact Lenses Compared to Commercially
Available Lenses
In the study done on antifungal contact lenses, when synthesizing the econazole-laden lenses, parameters of an 8.05
base curve and a 15.5 mm diameter were measured, which
are consistent with commercially available lenses (Ciolino et
al., 2011).

Preservation of Contact Lens through
Lyophilization (to prevent drug elution/
degradation) Effect on Lens Capability
Depending on the method used to impregnate the lenses with
drug, there exists a risk of the drug eluting out of the lens during
storage. In order to combat this, anti-fungal contact lenses were
lyophilized, a preservation process involving the freeze drying of
a substance and subsequent removal of water by a vacuum causing the water to go from an ice state directly to a gaseous one.
The fungicidal activity of the lyophilized lens was then assessed
and found to be intact, although the duration of its effectiveness
was reduced by 1 to 2 days (Ciolino et al., 2011).

Risk Factors and Drawbacks Associated with a DDCL
Although there is a lot of potential is this innovative drug delivery system, several potential downsides should be noted. There
are many consumers who do not wear contact lenses because
they find them uncomfortable or haven’t found the proper fit.
Others do not wear contact lenses because they have no refractive error and would thus need a special fitting session just
to wear a short-term lens. Additionally, glaucoma often affects
the geriatric population. Individuals of this population could also
have difficulty inserting and removing the lenses, however this
issue could be aided by an eye-care professional. These factors
could potentially minimize the market for such lenses. Another
problematic feature involves the drug-eluting property of the

42

lenses. Once removed by the patient any remaining drug may
continue to diffuse out. In the case of anti-fungal drugs, this
could have an effect on the development of resistant strains
while in the case of other drugs this may simply pose as a hazard
for children. (It should be noted though that with lenses controlled by lysozyme presence this undesired drug-elution may
be minimized).

Conclusion and Further Applications
Contact lenses for the treatment of glaucoma, fungal keratitis,
and allergic conjunctivitis have been synthesized and demonstrate much potential in effective treatment. However, the lenses are far from having a clinical relevance. Much more animal
and human testing is required prior to the necessary FDA-type
approvals. Although in this paper glaucoma, fungal keratitis, and
allergic conjunctivitis were discussed, research is also underway for additional ocular conditions such as, chronic dry eye
and bacterial infections (Legett, 2009), (ElShaer et al., 2016).
Additionally, the studies are working on embedding various drug
nanoparticles into lenses without obstructing optical transparency. Potentially, instead of drugs, various ocular-necessary vitamins and supplements can serve as the embedded nanoparticle.
As salt is iodized to promote proper thyroid function, perhaps
macular degeneration could be prevented by infusing contact
lenses with nanoparticles of lutein and zeaxanthin, two nutrients
vital to a healthy macula.
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